The goal of this activity is for learners to be better able to evaluate the current and emerging landscape for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), including the latest clinical data, developments in understanding of the role of genetics in therapeutic targets, as well as the value of biomarkers in ATTR-CM management and implications for improved patient outcomes.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1000732
- Start Date: 2024-04-25 05:00:00
- End Date: 2024-04-25 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- MOC Credit Details: ABIM - 0.75 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: BridgeBio Pharma, Inc. - Amount: 106500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Cardiovascular Disease, Hematology, Internal Medicine
Subscribe
Login
0 Comments
Oldest